JAK1 and cancer: This appeared partly due to enrichment of JAK1 truncating frameshift mutations, which were associated with reduced IFNγ response in human cancers, loss of IFN signalling in cell lines, and which have recently been shown to predict lack of response to immunotherapy in EC [48].